Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Withdrawn before enrolling · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Drugs used in chemotherapy, such as soblidotin and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of soblidotin and gemcitabine in treating patients with locally advanced or metastatic solid tumors.

Key facts

Study ID

NCT00072228

Run by

Daiichi Pharmaceuticals

Last updated by the study team

2013-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of New Mexico Cancer Research and Treatment Center — Albuquerque, New Mexico, United States
• Herbert Irving Comprehensive Cancer Center at Columbia University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.